MARKET WIREThe Motley Fool • 7h ago
Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?The Motley Fool report covering BioNTech SE (BNTX) market action, institutional positioning, and fundamental catalysts.
Why BNTX Stock slipped -1.08% Today — RQD Quant Desk Flash
$88.17 -1.08% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $87.83
BioNTech SE (BNTX) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $22.39B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on BNTX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is BNTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, BioNTech SE (NASDAQ: BNTX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $88.17 (-1.08% 1D, market cap $22.39B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, BNTX ranks #262 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does BNTX compare to EXEL and HALO in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BNTX carries a Roarable D+ (52/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, EXEL (Exelixis Inc.) holds a A grade (89/100 RQD, P/E 21.0x, ROIC 35.1%, cap $16.40B) and HALO (Halozyme Therapeutics Inc.) posts a B grade (75/100 RQD, P/E 47.0x, ROIC 18.0%, cap $14.89B). Among the 5-stock peer group, EXEL leads on earnings multiple (21.0x) while EXEL leads on capital efficiency (35.1% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for BNTX?
▼
For BioNTech SE (BNTX), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs. and sector rank #262 in Health Care, while primary risk factors center on Sensitive to high interest rates and tighter Federal Reserve market liquidity. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $87.83 (-0.38%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 12.4% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY • 50.1% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk C-
Each axis scored 0–20
12M PRICE TARGET CONE-2.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BNTX)Realized 20D OHLCV Swing Band: ±6.4%
Deterministic 5-Pillar Attribution (52/100 Composite)
🔍 WHY BNTX SCORES 52/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (31% of score)
Altman Z-Score 3.74 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9
▲ #2 Bullish Driver: Insider Conviction & Share Dilution+12/20 pts (23% of score)
SEC Form 4 / 13F Thermometer: 60% Net Buy • Cannibal Buyback (-1.24% YoY Shares)
▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$89.01+2.4% Next Q
60
Q2 (-2Q)Grade C$91.17-4.5% Next Q
57
Q3 (-1Q)Grade C$87.06+1.3% Next Q
55
CurrentGrade D+$88.17-1.1% Hist 90D α
52
Trajectory: C (60) → D+ (52)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a BNTX Turnaround Squeeze
While BNTX currently carries a cautious 52/100 (D+) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Clean SEC annual filing review with no major hidden accounting time-bombs.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($96.22) and Max Pain ($92.58) forces dealer call-delta covering toward $130.20.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-1.24% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $BNTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BNTX Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why BNTX Stock slipped -1.08% Today — RQD Quant Desk Flash
BioNTech SE (BNTX) slipped -1.08% to $88.17, trading at 19% of its 52-week range ($79.52 – $124). Stretched risk/reward at 33x P/E (10% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 19% of its 52-week range ($79.52 – $124) with RSI-14 at 43.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±6.4% around $88.17 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 52% gross margin and $494.8M annual free cash flow.
Live BNTX Headlines & Catalysts
MARKET WIRESeeking Alpha • 10h ago
BioNTech SE: Moving Past Covid (NASDAQ:BNTX)Seeking Alpha report covering BioNTech SE (BNTX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 13h ago
BioNTech SE (BNTX) Stock ForecastsYahoo Finance report covering BioNTech SE (BNTX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 16h ago
Biontech SE Stock (BNTX) Closed Down by 7.13% on Oct 13: Drivers Behind the MovementTradingKey report covering BioNTech SE (BNTX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 19h ago
BioNTech SE Estimates – NASDAQ:BNTXTradingView report covering BioNTech SE (BNTX) market action, institutional positioning, and fundamental catalysts.
RISK WATCHBenzinga • 22h ago
Why Is BioNTech Stock Falling Tuesday?Benzinga report covering BioNTech SE (BNTX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRE24/7 Wall St. • 1d ago
Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher24/7 Wall St. report covering BioNTech SE (BNTX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Motley Fool • 1d ago
Moderna Is Now Worth More Than 3X as Much as BioNTech. Which Biotech Stock Is the Smarter Pick?The Motley Fool report covering BioNTech SE (BNTX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 4d ago
BMY Q3 Earnings Tops Estimates, Higher Charges Weigh on OutlookBristol Myers tops Q3 earnings and revenue estimates as Growth Portfolio sales and Eliquis demand drive growth, but higher IPRD charges prompt a cut to 2026 EPS guidance.
RISK WATCHYahoo • 5d ago
BioNTech (BNTX) Phase 3 Breast Cancer Win Comes With A Lung Safety WarningBioNTech (NasdaqGS:BNTX) and DualityBio reported positive topline results from the DYNASTY-Breast02 Phase 3 trial in HR+/HER2-low metastatic breast cancer, including a statistically significant improvement in progression
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BNTX)
- ✓Walkthrough of BNTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
BNTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.25%⚡ TESTING RESISTANCE
2026-11-02O $87.99H $89.13L $87.99C $88.17VOL 692.7K
RES: $89.93SUP: $84.78SMA50: $96.22SMA200: $96.91
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
BNTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
25.3%/yr Implied 5Y Growth
vs. +14.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on BNTX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for BNTX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BNTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BNTX)
Health Care Rank #262 of 1016
⚔️ EXEL vs BNTX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (BNTX vs. EXEL, HALO, NBIX, BIIB)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, BioNTech SE (BNTX) ranks #262 by composite RQD confidence (52/100, grade D+) and #69 by equity capitalization ($22.39B). Within this direct 5-issuer industry benchmark cohort, EXEL leads on earnings valuation at 21.0x trailing P/E, while EXEL leads on capital efficiency and profitability with 35.1% ROIC and 96.0% gross margin. EXEL currently holds the highest overall quantitative score in the immediate peer group at 89/100 (A) compared with BNTX at 52/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BNTX
ACTIVE
BioNTech SE | D+ | 52/100 | 32.8x | — | 9.9% | -1.08% | $22.39B | Benchmark Subject |
| EXEL Exelixis Inc. | A | 89/100 | 21.0x | 96.0% | 35.1% | +4.82% | $16.40B | /exel-vs-bntx → |
| HALO Halozyme Therapeutics Inc. | B | 75/100 | 47.0x | 83.6% | 18.0% | -0.21% | $14.89B | /halo-vs-bntx → |
| NBIX Neurocrine Biosciences Inc. | B | 73/100 | 31.1x | 96.0% | 15.7% | -0.19% | $14.88B | /nbix-vs-bntx → |
| BIIB Biogen Inc. | B | 74/100 | 28.5x | 75.7% | 6.4% | +1.59% | $36.90B | /biib-vs-bntx → |
2. BNTX Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTBioNTech SE (BNTX) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $22.39B, trailing P/E of 32.8x, forward P/E of 27.6x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of —, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 8/9.
3. BNTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs BNTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, BioNTech SE (NASDAQ: BNTX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $88.17 (-1.08% 1D, market cap $22.39B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, BNTX ranks #262 in composite RQD confidence.
How does BNTX compare to EXEL and HALO in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BNTX carries a Roarable D+ (52/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, EXEL (Exelixis Inc.) holds a A grade (89/100 RQD, P/E 21.0x, ROIC 35.1%, cap $16.40B) and HALO (Halozyme Therapeutics Inc.) posts a B grade (75/100 RQD, P/E 47.0x, ROIC 18.0%, cap $14.89B). Among the 5-stock peer group, EXEL leads on earnings multiple (21.0x) while EXEL leads on capital efficiency (35.1% ROIC).
What are the biggest fundamental strengths and SEC risk factors for BNTX?
For BioNTech SE (BNTX), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs. and sector rank #262 in Health Care, while primary risk factors center on Sensitive to high interest rates and tighter Federal Reserve market liquidity. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Where is BNTX trading relative to its 50-day, 200-day, and 52-week technical levels?
BNTX last traded at $88.17 (-1.08% on volume of 631,916 shares), positioning the stock -8.37% below its 50-day simple moving average ($96.22) and -9.02% below its 200-day simple moving average ($96.91). Across its 52-week range of $79.52 to $124.00, BNTX sits at the 19.4% percentile with a 14-day RSI of 43.4 (NEUTRAL RANGE) and an implied next-earnings move of ±6.4% ($82.53 to $93.81).
BNTX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is BNTX stock moving today?
Why BNTX Stock slipped -1.08% Today — RQD Quant Desk Flash. Stretched risk/reward at 33x P/E (10% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 52/100 (D+)
✓ STAGE-C NUMBER FIREWALL VERIFIED
BNTX — BioNTech SE: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:09:28Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, BNTX scores 52 out of 100, grade D+, labeled "Roarable Sell — Weak Fundamentals / Trim." The five pillars are:
- Fundamental Cash Engine: 11 / 20 (ROIC 9.9%; FCF yield 2.21%). This is the pillar that most directly reflects economic return on capital. The score indicates modest returns relative to the scale of the business, and the free-cash-flow yield at 2.21% offers limited cash return at the current price.
- Whale 13F Flow: 5 / 20 (institutional accumulation and options positioning). This is the weakest pillar and signals that institutional positioning is not presently a support for the stock.
- Insider Conviction: 12 / 20 (SEC Form 4 and Congressional PTR cluster flow). A moderate reading; insider signals are neither strongly supportive nor strongly negative.
- Macro Regime Fit: 8 / 20 (Beta 1.02; sector sensitivity). Beta of 1.02 means the stock has moved roughly in line with the broader market, and the low pillar score indicates limited alignment with the current macro regime.
- Forensic Balance Sheet: 16 / 20 (Altman Z 3.74; Piotroski F 8/9; Debt/Equity 0.39). This is the strongest pillar, indicating the balance sheet is a relative strength.
For a prospective investor, the rating frames BNTX as a company with a financially sound balance sheet but weak institutional sponsorship, modest capital returns, and a valuation that carries a premium on earnings (P/E TTM 32.8). The upside case rests on balance-sheet resilience and any improvement in cash generation; the valuation tradeoff is that a 32.8 trailing P/E and 21 EV/EBITDA leave limited margin for error if earnings disappoint. The rating does not constitute personalized financial advice.
Snapshot
Business
BioNTech SE, trading on NASDAQ under the ticker BNTX as an American Depositary Share, operates in the Health Care sector within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the profile, the company's market capitalization is $22.4B. The source data does not describe its products, customers, or revenue model in detail.
Recent Catalysts & News Wire Analysis
Per the recent news feed, six items reference BNTX:
- A Motley Fool report (YELLOW) asks whether the stock is still a buy following a "major setback" for a cancer vaccine.
- A Seeking Alpha report (YELLOW) is titled "Moving Past Covid."
- A Yahoo Finance report (YELLOW) covers stock forecasts.
- A TradingKey report (YELLOW) notes the stock closed down 7.13% on Oct 13.
- A TradingView report (YELLOW) covers analyst estimates.
- A Benzinga report (RED, RISK WATCH) asks why the stock is falling on a Tuesday.
The Benzinga item is the only RISK WATCH flag in the feed. No proprietary signals are present in the Butterfly graph. The feed summaries are generic and do not disclose the specific cause of the cited declines or setbacks.
Open Questions
- What specific setback affected the cancer vaccine program referenced in the news feed, and what is its financial significance?
- What are the reported revenue, operating income, and free cash flow across recent periods to confirm the margin and FCF yield trends?
- What is the analyst consensus rating and price target distribution, and how does the current $89.13 price compare?
- What institutional (13F) and insider (Form 4) positioning exists, given the Whale 13F pillar scored 5 of 20?
- What drove the 52-week range of $79.52 to $124, and where does the current price sit within that range over time?
BNTX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for BioNTech SE (BNTX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE The Motley Fool • 7h ago
Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy? The Motley Fool report covering BioNTech SE (BNTX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 10h ago
BioNTech SE: Moving Past Covid (NASDAQ:BNTX) Seeking Alpha report covering BioNTech SE (BNTX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 13h ago
BioNTech SE (BNTX) Stock Forecasts Yahoo Finance report covering BioNTech SE (BNTX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 16h ago
Biontech SE Stock (BNTX) Closed Down by 7.13% on Oct 13: Drivers Behind the Movement TradingKey report covering BioNTech SE (BNTX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 19h ago
BioNTech SE Estimates – NASDAQ:BNTX TradingView report covering BioNTech SE (BNTX) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Benzinga • 22h ago
Why Is BioNTech Stock Falling Tuesday? Benzinga report covering BioNTech SE (BNTX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE 24/7 Wall St. • 1d ago
Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher 24/7 Wall St. report covering BioNTech SE (BNTX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Motley Fool • 1d ago
Moderna Is Now Worth More Than 3X as Much as BioNTech. Which Biotech Stock Is the Smarter Pick? The Motley Fool report covering BioNTech SE (BNTX) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
BNTX Bull vs. Bear Conversation Board — What's Your Call at $88.17?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BNTX 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $96.26 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is BNTX (D+ • RQD 52/100) a Buy at $89.13?
Welcome to the BNTX (BioNTech SE) Roar Pit. Current RQD Composite is 52/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (32.8x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $66.85 (-25.0%)
Spot @ $89.13 Pump the brakes on BNTX — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on BNTX, but look at what you are paying: 32.8x trailing P/E with tightening sector spreads. Unless BioNTech SE expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
QU QuantViper Verified K Arena Trader 🐂 BULLISH
🎯 Target: $114.09 (+28.0%)
Spot @ $89.13 BNTX cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on BNTX, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $89.13 (52-wk range $79.52 - $124.00), any beat on forward guidance forces shorts and underweight funds to chase.